Berkeley Advanced Biomaterials Granted FDA Approval
to Market Bi-Ostetic™ Products in U.S.

01/30/2003 Berkeley, California. The U.S. Food and Drug Administration has approved Bi-Ostetic™ granules and blocks. The company's Ostetic product line of synthetic bone fillers provides high-quality, cost-effective solutions for orthopedic care.

"FDA approval of Bi-Ostetic™ is a key milestone for our compnay" according to Berkeley Advanced Biomaterials co-founder and CEO Dr. François Génin. "Earlier this year the FDA approved our Cem-Ostetic™ putty product. With approval of Bi-Ostetic™ and Cem-Ostetic™, Berkeley Advanced Biomaterials now offers a complete synthetic bone graft solution in the U.S."

Bi-Ostetic™ cancellous and cortical granues provide a complete sets of bone graft fillers. Bi-Ostetic™ is the natural alternative to autografts or cadaver bone and an ideal choice for the demands of orthopedic surgery. The spongy granules are bioceramics with true interconnected porosity that mimic the cancellous bone structure in order to enhance osteo-conduction and ensure complete and rapid bone in-growth.

In the block formulation, orthopedic surgeons have another way to deliver Bi-Ostetic™ during surgery. Doctors can cut blocks as necessary to fill bone voids.

Approved early this near, Cem-Ostetic™ is a neutral pH bone putty that contains several calcium-based biocompatible salts. The putty is created simply by combining pre-measured water and powder. The putty can be injected or formed into an implant and hardens in less than 5 minutes.

According to Ken Trauner, MD, "Bi-Ostetic™ gives surgeons a cost-effective alternative to other synthetic bone fill products on the market. With Bi-Ostetic™, Berkeley Advanced Biomaterials brings additional solutions to the operating room."

Both Bi-Ostetic™ and Cem-Ostetic™ are currenty available. For more information on the Ostetic product line and on how to purchase Ostetic products, please visit the company's web site: http://www.ostetic.com.

About Berkeley Advanced Biomaterials:
Formed in 1996 to develop biomaterials for orthopedic applications, BAB introduced its Ostetic line of bone filler materials in 2002. The company continues to work with academic and corporate laboratories to develop novel biomaterials. BAB is a privately held company with headquarters in Berkeley, California. For more information, visit the company's website: http://www.ostetic.com.